Advanced glycation endproducts and diabetic nephropathy

被引:31
作者
Makita, Z
Yanagisawa, K
Kuwajima, S
Yoshioka, N
Hasunuma, Y
Koike, T
机构
[1] Second Department of Medicine, Hokkaido University School of Medicine, Sapporo
关键词
D O I
10.1016/1056-8727(95)80018-A
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic nephropathy is currently the single largest cause of endstage renal disease (ESRD) in the United States and many European countries. The primary cause for the development of diabetic complications (including diabetic nephropathy) is persistent exposure to hyperglycemia, although genetic and other incompletely understood factors also play an important role. Although much consideration has been given to the pathogenesis and genetics of the disease itself, the mechanisms by which persistent exposure to hyperglycemia cause biochemical and metabolic alterations have been very sketchily understood. Recently, a growing body of evidence has linked the accumulation of the late products of glucose-protein interaction to a variety of chronic complications, including diabetic nephropathy. The formation of irreversible advanced glycosylation endproducts (AGEs) resulting from the spontaneous reaction between glucose and proteins occur most noticeably on long-lived structural proteins. Recent studies demonstrate that the pathogenesis of diabetic nephropathy is caused by the hyperglycemia-accelerated formation of AGEs. Also, reactive AGE peptides in the circulation are thought to play a role as a new version of so called middle molecule toxic substances. This evidence is opening a new window for our understanding of the pathogenesis of diabetic nephropathy.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 26 条
[1]   AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING [J].
BROWNLEE, M ;
VLASSARA, H ;
KOONEY, A ;
ULRICH, P ;
CERAMI, A .
SCIENCE, 1986, 232 (4758) :1629-1632
[2]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[3]   LIPID ADVANCED GLYCOSYLATION - PATHWAY FOR LIPID OXIDATION IN-VIVO [J].
BUCALA, R ;
MAKITA, Z ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) :6434-6438
[4]   MODIFICATION OF LOW-DENSITY-LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL-INSUFFICIENCY [J].
BUCALA, R ;
MAKITA, Z ;
VEGA, G ;
GRUNDY, S ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) :9441-9445
[5]   ADVANCED GLYCOSYLATION PRODUCTS QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT VASODILATATION IN EXPERIMENTAL DIABETES [J].
BUCALA, R ;
TRACEY, KJ ;
CERAMI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) :432-438
[6]   ENDOTHELIAL RECEPTOR-MEDIATED BINDING OF GLUCOSE-MODIFIED ALBUMIN IS ASSOCIATED WITH INCREASED MONOLAYER PERMEABILITY AND MODULATION OF CELL-SURFACE COAGULANT PROPERTIES [J].
ESPOSITO, C ;
GERLACH, H ;
BRETT, J ;
STERN, D ;
VLASSARA, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (04) :1387-1407
[7]  
FUH H, 1992, DIABETES, V41, pA9
[8]   A NEW FORM OF AMYLOID PROTEIN ASSOCIATED WITH CHRONIC-HEMODIALYSIS WAS IDENTIFIED AS BETA-2-MICROGLOBULIN [J].
GEJYO, F ;
YAMADA, T ;
ODANI, S ;
NAKAGAWA, Y ;
ARAKAWA, M ;
KUNITOMO, T ;
KATAOKA, H ;
SUZUKI, M ;
HIRASAWA, Y ;
SHIRAHAMA, T ;
COHEN, AS ;
SCHMID, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 129 (03) :701-706
[9]   ADVANCED GLYCOSYLATION ENDPRODUCT-SPECIFIC RECEPTORS ON HUMAN AND RAT T-LYMPHOCYTES MEDIATE SYNTHESIS OF INTERFERON-GAMMA - ROLE IN TISSUE REMODELING [J].
IMANI, F ;
HORII, Y ;
SUTHANTHIRAN, M ;
SKOLNIK, EY ;
MAKITA, Z ;
SHARMA, V ;
SEHAJPAL, P ;
VLASSARA, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2165-2172
[10]   AMINOGUANIDINE DECREASES URINARY ALBUMIN AND HIGH-MOLECULAR-WEIGHT PROTEINS IN DIABETIC RATS [J].
ITAKURA, M ;
YOSHIKAWA, H ;
BANNAI, C ;
KATO, M ;
KUNIKA, K ;
KAWAKAMI, Y ;
YAMAOKA, T ;
YAMASHITA, K .
LIFE SCIENCES, 1991, 49 (12) :889-897